Search research articles
Contact Us
Filters
Showing results (101-110 of 190) with videos related to
Page
of 19
Sort By:
Pharmacoeconomics
|
May 8, 2022
Modeling the Ex Ante Clinical Real Option Value in an Innovative Therapeutic Area: ALK-Positive Non-Small-Cell Lung Cancer
Woojung Lee, William B Wong, Stacey Kowal, et al.
The Journal of Infectious Diseases
|
June 14, 2011
Global eradication of measles: an epidemiologic and economic evaluation
Ann Levin, Colleen Burgess, Louis P Garrison, et al.
Contemporary Clinical Trials
|
September 18, 2012
The value of comparative effectiveness research: projected return on investment of the RxPONDER trial (SWOG S1007)
William B Wong, Scott D Ramsey, William E Barlow, et al.
Journal of Medical Economics
|
October 13, 2012
Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis
Victor Barzey, Michael B Atkins, Louis P Garrison, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
April 25, 2024
Estimating the Allocation of the Economic Value Generated by Utilization of All-Oral Direct-Acting Antivirals for Hepatitis C in the United States, 2015 to 2019
Louis P Garrison, Boshen Jiao, Zizi Elsisi, et al.
Cancer
|
June 19, 2013
Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status
Louis P Garrison, Deepa Lalla, Melissa Brammer, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
November 12, 2019
Projected Cost-Effectiveness for 2 Gene-Drug Pairs Using a Multigene Panel for Patients Undergoing Percutaneous Coronary Intervention
M Ragan Hart, Louis P Garrison, Debra L Doyle, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
April 13, 2019
Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States
Louis P Garrison, Joseph Babigumira, Clément Tournier, et al.
BMC Health Services Research
|
October 23, 2009
Potential impact of task-shifting on costs of antiretroviral therapy and physician supply in Uganda
Joseph B Babigumira, Barbara Castelnuovo, Mohammed Lamorde, et al.
Pharmacoeconomics
|
September 24, 2021
Principles of Economic Evaluation in a Pandemic Setting: An Expert Panel Discussion on Value Assessment During the Coronavirus Disease 2019 Pandemic
Yumi Asukai, Andrew Briggs, Louis P Garrison, et al.
Page
of 19
Search research articles
Search
Showing results (101-110 of 190) with videos related to
Sort By:
Page
of 19
Pharmacoeconomics
|
May 8, 2022
Modeling the Ex Ante Clinical Real Option Value in an Innovative Therapeutic Area: ALK-Positive Non-Small-Cell Lung Cancer
Woojung Lee, William B Wong, Stacey Kowal, et al.
The Journal of Infectious Diseases
|
June 14, 2011
Global eradication of measles: an epidemiologic and economic evaluation
Ann Levin, Colleen Burgess, Louis P Garrison, et al.
Contemporary Clinical Trials
|
September 18, 2012
The value of comparative effectiveness research: projected return on investment of the RxPONDER trial (SWOG S1007)
William B Wong, Scott D Ramsey, William E Barlow, et al.
Journal of Medical Economics
|
October 13, 2012
Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis
Victor Barzey, Michael B Atkins, Louis P Garrison, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
April 25, 2024
Estimating the Allocation of the Economic Value Generated by Utilization of All-Oral Direct-Acting Antivirals for Hepatitis C in the United States, 2015 to 2019
Louis P Garrison, Boshen Jiao, Zizi Elsisi, et al.
Cancer
|
June 19, 2013
Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status
Louis P Garrison, Deepa Lalla, Melissa Brammer, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
November 12, 2019
Projected Cost-Effectiveness for 2 Gene-Drug Pairs Using a Multigene Panel for Patients Undergoing Percutaneous Coronary Intervention
M Ragan Hart, Louis P Garrison, Debra L Doyle, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
April 13, 2019
Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States
Louis P Garrison, Joseph Babigumira, Clément Tournier, et al.
BMC Health Services Research
|
October 23, 2009
Potential impact of task-shifting on costs of antiretroviral therapy and physician supply in Uganda
Joseph B Babigumira, Barbara Castelnuovo, Mohammed Lamorde, et al.
Pharmacoeconomics
|
September 24, 2021
Principles of Economic Evaluation in a Pandemic Setting: An Expert Panel Discussion on Value Assessment During the Coronavirus Disease 2019 Pandemic
Yumi Asukai, Andrew Briggs, Louis P Garrison, et al.
Page
of 19